check_circleStudy Completed

Hypertension, Pulmonary

Bayer Identifier:

16843

ClinicalTrials.gov Identifier:

NCT02117791

EudraCT Number:

Not Available

EU CT Number:

Not Available
Prospective, non-interventional, multi-center post-authorization safety study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

Trial purpose

This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/ persistent or recurrent CTEPH after surgical treatment. It is planned to include a total of 400 patients (valid for safety analysis). This study is performed as an all-case investigation. The treatment of Riociguat is performed based on the product label in Japan. The standard observation period is 12 months from the 1st treatment of Riociguat. Safety and effectiveness are evaluated at 4th and 12th month. In addition, the extension observation is carried out once a year for 7 years at the longest to collect information on safety and effectiveness as long as Riociguat treatment continues. When the treatment of Riociguat is terminated, observation of a patient ends. For each patient, the investigator records data as defined in the protocol at each evaluation point by using the Electronic Data Capture (EDC) system. The duration of the study is approximately 9 years from launch.

Key Participants Requirements

Sex

Both

Age

NaN - N/A
  • - Patients who are treated with Riociguat for CTEPH

  • - Patients who are contraindicated based on the product label

Trial summary

Enrollment Goal
1298
Trial Dates
July 2014 - September 2023
Phase
N/A
Could I Receive a placebo
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Recruiting
Many Locations, Japan

Primary Outcome

  • Number of participants with treatment emergent adverse events and adverse drug reactions
    date_rangeTime Frame:
    up to 8 years
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Change from baseline in 6MWD (6-Minute Walking Distance) after 4 and 12 months
    date_rangeTime Frame:
    baseline and 4 months, and 12 months
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline in Pulmonary Vascular Resistance (PVR) after 4 and 12 months
    date_rangeTime Frame:
    baseline and 4 months, and 12 months
  • Change from baseline in TRPG (Tricuspid Regurgitation Pressure Gradient) after 4 and 12 months
    date_rangeTime Frame:
    baseline and 4 months, and 12 months
  • Change from baseline in BNP/NT-pro BNP after 4 and 12 months
    date_rangeTime Frame:
    baseline and 4 months, and 12 months
  • Change from baseline in WHO (World Health Organization) functional class after 4 and 12 months
    date_rangeTime Frame:
    baseline and 4 months, and 12 months
  • Time to Clinical Worsening
    The first occurrence of the following events is recorded and will be considered for the calculation of the combined endpoint: • Death (all-cause mortality) • Heart/lung transplantation • Rescue Pulmonary Endarterectomy, Rescue Balloon Pulmonary Angioplasty or Hospitalization due to persistent worsening of Pulmonary Hypertension • Start of new PH specific treatment due to worsening Pulmonary Hypertension. • Persistent decrease in 6MWD due to worsening pulmonary hypertension • Persistent worsening of functional class due to deterioration of Pulmonary Hypertension.
    date_rangeTime Frame:
    up to 8 years
    enhanced_encryption
    Safety Issue:
    No

Trial design

Drug Use Investigation of Riociguat for ChronicThromboembolic Pulmonary Hypertension (CTEPH)
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A